Boston ratchets up Watchman efforts as clinical data builds
This article was originally published in Clinica
Executive Summary
Medtech companies chomping at the bit to see their new product take off in the market might do well to heed the advice of Kenneth Stein, senior vice-president and chief medical officer of Boston Scientific’s cardiac rhythm management division: “There is a natural process in the adoption of technology; you wouldn’t want to see your technology going ahead of clinical evidence.”
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.